Furthermore, treatment of empagliflozin in T2DM patients at high risk of cardiovascular disease led to a reduction in IL-1β secretion due to reduced NLRP3 inflammasome activation [189]. The gene discussed is IL1B; the disease is cardiovascular disorder.